A clinical examination of UK pharmaceuticals

Kyle Williams, manager of the JPM UK Equity Growth Fund, examines the pharmaceuticals sector.

Go to the profile of Kyle Williams
Nov 22, 2018
0
0

Healthy growth

The pharmaceuticals sector has, for many years, been one of the classic growth sectors driven by a growing, ageing population with significant unmet medical need, and better access to healthcare. At the same time advances in medical knowledge and the emergence of new technologies are revolutionising the way medicines are developed, tested, and delivered to patients. From humble beginnings in the apothecaries of Babylon, the global pharmaceutical industry today (prescription and over-the-counter products) generates over one trillion dollars in revenues each year.

Global prescription drug sales ($m) – flatlining?

  Source: IQVIA, HSBC

Coming down with something

Over the past decade, however, expectations for future growth have come down significantly. A number of the blockbuster drugs discovered in the early 1990s have lost their patent protection over the past decade, allowing generic alternatives to enter the market at a steep discount. Hence the term “patent cliff”. Meanwhile, the outlook for pricing and volume expansion is becoming less attractive given sustained pressure on drug pricing in Europe, the growing size and bargaining power of health insurers in the United States, and mounting competitive pressure in emerging markets. A tweet from Democratic presidential candidate Hillary Clinton in September 2015 attacking high drug prices thrust the pharmaceutical sector into the political arena, creating additional uncertainty for future earnings that is still palpable today. All things put together, these challenges have led to a sharp rebasing of expectations for the industry.

In need of a check-up

In the JPM UK Equity Growth Fund we look for high quality companies that are exceeding expectations. Despite the headwinds facing the industry from a top down perspective, this year we have been buying UK pharmaceuticals, which we think offer genuine growth opportunities. Both AstraZeneca and GlaxoSmithKline have been surprising positively. For example, GlaxoSmithKline’s new shingles vaccine (Shingrix) generated sales of £110 million in the first quarter, nearly triple analyst estimates of £40 million, taking a 90% market share just five months after launching in the US. Meanwhile, AstraZeneca’s renewed focus on research and development productivity is delivering clear benefits with clinical trial results across the oncology portfolio (Tagrisso, Lynparza, Infimzi) coming in well ahead of market expectations, alongside a return to positive sales growth for the first time since 2010.

The results are back

The Pharmaceuticals & Biotechnology industry group has been one of the best performers in the UK market in 2018, returning 18.8% to 31 October 2018. Despite exceeding expectations, the sector has seen only modest earnings-per-share (EPS) revisions, hence this performance has been driven almost entirely by a re-rating of the sector. The market is currently forecasting +5.4% EPS growth over the next 12 months, below the expected +7.0% growth for the broader UK market. If the strong underlying fundamentals continue as per recent quarters we see scope for EPS upgrades, and further outperformance.

Source: Bloomberg

  Kyle Williams is a portfolio manager for the JPM UK Equity Growth Fund.

Advertisement

Find out more about our UK capabilities

 

 

For Professional Clients only – not for Retail use or distribution.

This is a marketing communication and as such the views contained herein are not to be taken as an advice or recommendation to buy or sell any investment or interest thereto. Reliance upon information in this material is at the sole discretion of the reader. Any research in this document has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are, unless otherwise stated, J.P. Morgan Asset Management’s own at the date of this document. They are considered to be reliable at the time of writing, may not necessarily be all inclusive and are not guaranteed as to accuracy. They may be subject to change without reference or notification to you. It should be noted that the value of investments and the income from them may fluctuate in accordance with market conditions and investors may not get back the full amount invested. Past performance and yield are not a reliable indicator of current and future results. There is no guarantee that any forecast made will come to pass. J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide. To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy www.jpmorgan.com/emea-privacypolicy.This communication is issued in the UK by JPMorgan Asset Management (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. Registered in England No. 01161446. Registered address: 25 Bank Street, Canary Wharf, London E14 5JP. 0903c02a82439ce4

Go to the profile of Kyle Williams

Kyle Williams

Portfolio Manager, J.P. Morgan Asset Management

No comments yet.